Patricia Inacio, PhD,  science writer—

A conversational bot is being developed at the University of Illinois at Urbana-Champaign (UIUC) to promote COVID-19 vaccinations among people with multiple sclerosis (MS) who are hesitant to take the vaccine. The project is meant to provide accessible digital health information about the vaccines to more vulnerable populations…

Therini Bio announced raising $17 million in a financing round to speed the development of an antibody that might treat people with inflammatory conditions, such as multiple sclerosis (MS), associated with damage to blood vessels. These funds will also support work aiming to move this antibody, targeting the protein…

The Consortium of Multiple Sclerosis Centers (CMSC) has launched a monthly webinar series, in partnership with NeurologyLive, to keep doctors and others treating people with multiple sclerosis (MS) informed of the latest in disease care and research. Called “The Ever Changing Face of MS,” the series opened on…

The multiple sclerosis (MS) treatment Gilenya (fingolimod) is associated with a 16% greater risk of infections, compared with a placebo or control treatment, according to data from 12 randomized clinical trials. The findings were published in a study, “Incidence and Risk of Infection Associated With Fingolimod in Patients…

Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease. More specifically, the approval includes patients with either clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS), who have…

A genetic variant in the WNT9B gene and vitamin D response are both associated with a greater risk of relapses in people with multiple sclerosis (MS), a recent study in Belgium has found. The study, “Genetic variation in WNT9B increases relapse hazard in multiple sclerosis,” was published in the journal…

A Phase 3 trial investigating GA Depot, a long-acting, once-a-month injectable formulation of glatiramer acetate, is seeking patients with relapsing forms of multiple sclerosis (MS). The global study (NCT04121221) aims to include 960 adults, ages 18 to 55, diagnosed with clinically isolated syndrome (CIS), relapsing-remitting…

Off-label treatment with Tysabri (natalizumab) significantly lessens disease activity and reduces the number of relapses per year in patients with pediatric-onset multiple sclerosis (POMS), real-world data from Portugal show. The treatment also was considered safe in this population, in agreement with earlier studies. These findings support the usefulness…

Pilates, done regularly, can significantly improve balance and posture in men with multiple sclerosis (MS), helping them to avoid falls and the injuries they can bring, a small randomized trial in Iran reports. The study, “Effect of Twelve weeks Pilates training on functional balance of male patients…

The National Multiple Sclerosis Society (NMSS) is helping Pack Health, a patient engagement platform, to optimize and expand its digital health coaching program to assist people living with multiple sclerosis (MS). Building on what it has learned through work with the NMSS, Pack Health aims to bring its patient-centered and…

GeNeuro has completed patient enrollment in its ProTEct-MS Phase 2 clinical trial evaluating temelimab as a treatment for multiple sclerosis (MS), the company announced. The study (NCT04480307), taking place at the Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, Sweden, has enrolled 42 people with relapsing MS whose…

The levels of KIF5A protein are elevated in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of people with progressive multiple sclerosis (MS) and, further, are correlated with disease progression measures in patients with relapsing-remitting MS (RRMS), a new study shows. These…

Imatinib, a cancer treatment, stopped an injury response mechanism of the central nervous system (CNS) from activating, damage to which is a hallmark of multiple sclerosis (MS), an early study reported. Treatment with imatinib lessened immune cell infiltration and eased disease progression in mouse models of MS. Study researchers…

Desi Harrison, a multiple sclerosis (MS) patient and president of the nonprofit MS Warriors for a Cause, has donated $700,000 to support the Ochsner Neuroscience Institute. The funds will help support research and care at the Ochsner Multiple Sclerosis Center to ensure that patients — like Harrison, who…

Reduced exposure to sunlight, previously reported as a risk factor for developing multiple sclerosis (MS), also seems to increase the risk for relapse and worsening disability, data from two clinical studies suggest. The beneficial effects of sunlight exposure were linked to increased levels of vitamin D, but also modulation…

New research in mice suggests that poor recycling of cholesterol in the brain impairs the repair of myelin, the protective coat surrounding nerve cells that is lost in multiple sclerosis (MS). Pharmacological stimulation of cholesterol synthesis by brain immune cells — called microglia — boosted the regeneration of myelin,…

The levels of a protein called Neuregulin-1 beta 1 (Nrg-1beta1) decline with the onset and progression of multiple sclerosis (MS), a new study suggests. The findings support the potential of Nrg-1beta1 as a predictor of MS risk and progression and suggest that restoring its levels may help halt disease…

Despite having more severe first and second relapses, children with relapsing-remitting multiple sclerosis (RRMS) tend to recover better than adults with the disease, according to a study. Better recovery in children may be linked to the activation of genes that, in turn, impair the activation of immune cells driving…

Adolescents with multiple sclerosis (MS) have lower levels of fitness compared with healthy teenagers of the same age and a sex, a study suggests. Findings also demonstrated that among younger MS patients, higher levels of fitness were associated with lower disease activity and disability. The study “Youth with…

Women who have never given birth are more likely to develop early onset of progressive multiple sclerosis, according to a new study, which also found that a woman’s number of pregnancies showed a positive effect in delaying the disease. In addition, entering menopause earlier, before the age of 46,…

Progressive multiple sclerosis (MS) is the focus of the 2020 virtual European Multiple Sclerosis Platform (EMSP) annual meeting that runs though Friday, Nov. 20. Registration is free for the two-day conference. Those interested in participating can register here. According to a EMSP press release, topics to be discussed include the most…

Note: This story was updated Aug. 17, 2021, to note that T.gondii infection is a risk factor for rheumatoid arthritis and lupus, not a protective factor.  Toxoplasmosis, an infection by the parasite Toxoplasma gondii, may confer a certain level of protection against multiple sclerosis (MS), according…

The brain volume of people with relapsing-remitting multiple sclerosis (RRMS) undergoes a dynamic cycle of enlargement and contractions, a new study shows. Patients with a lower volume (contractions) had less severe MS and a shorter disease duration, the study found. Overall, these findings suggest that frequent monitoring of the…

Extracellular vesicles (EVs), tiny sacs released from myelin-producing cells called oligodendrocytes, may help dampen the immune system’s attack against myelin, whose loss is the hallmark of multiple sclerosis (MS), a new mouse study shows. The findings suggest that oligodendrocytes-released EVs could work as an universal immunotherapy for MS…

A pathway controlled by three proteins — Daam2, Nedd4, and VHL — was identified by researchers as a key regulator of myelin production during central nervous system development and regeneration after injury. Myelin, the protective fatty layer that covers nerve fibers and helps to speed transmission of signals between nerve cells,…

People with multiple sclerosis (MS) are among the high-risk groups advised to avoid dental amalgams — silver-colored fillings that are 50% mercury — under new recommendations issued by the U.S. Food and Drug Administration (FDA). Amalgams can be used by dentists to restore the structure and surfaces of teeth damaged by decay.

Dutch Amarna Therapeutics announced a research collaboration with Spanish Progreso y Salud Foundation (FPS) to investigate the efficacy of its gene therapy delivery technology in multiple sclerosis (MS) and diabetes. MS is thought to be caused by immune-mediated inflammation that damages myelin — an insulating sheath around nerve…

People with multiple sclerosis (MS) have a higher burden of mental disorders than healthy people or people with rheumatoid arthritis, a French population-based study suggests. The study, “Prevalence of mental disorders is higher in patients with multiple sclerosis than in the general population or in patients with…

Immune B-cells are more abundant and have a pro-inflammatory profile in the cerebrospinal fluid (CSF), the fluid that bathes the central nervous system,  compared to blood in people with relapsing-remitting multiple sclerosis (RRMS), a study reports. The results suggest that therapeutic strategies targeting the CSF B-cells could constitute a…

Children with multiple sclerosis (MS) recover more quickly and “significantly better” from relapses than do adults — patients with disease onset at age 18 or older, researchers reported. The study, “Improved relapse recovery in paediatric compared to adult multiple sclerosis,” was published in the journal Brain. Relapses and…